Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 84.85 |
|---|---|
| High | 84.94 |
| Low | 76.03 |
| Bid | 76.00 |
| Offer | 78.92 |
| Previous close | 73.33 |
| Average volume | 3.78m |
|---|---|
| Shares outstanding | 192.71m |
| Free float | 170.38m |
| P/E (TTM) | -- |
| Market cap | 14.13bn USD |
| EPS (TTM) | -4.19 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 21:00 GMT.
More ▼
- BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
- BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
- BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
- BridgeBio to Participate in the J.P. Morgan Healthcare Conference
- BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio to Participate in December Investor Conferences
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
More ▼
